Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG5
- Development stage
- Preclinical
- Lead developer
- Sungening
- Modality
- Small Molecules
01
Overview
SG5 is a small molecule inhibitor targeting the PRMT5-MTA complex, currently in preclinical development by Sungening for the treatment of solid tumors. PRMT5 (Protein Arginine Methyltransferase 5) is an epigenetic enzyme that methylates arginine residues on various proteins. In cancers characterized by MTAP (methylthioadenosine phosphorylase) deletion, the metabolite methylthioadenosine (MTA) accumulates and binds to PRMT5, creating a unique molecular vulnerability. SG5 is designed to selectively target this PRMT5-MTA complex, inducing synthetic lethality specifically in MTAP-deficient tumor cells while minimizing effects on healthy tissues that lack MTA accumulation.
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on SG5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG5.